Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.72 |
| ▸ | CDC25A | P30304 | 2/20 | 0.53 |
| ▸ | CDC25B | P30305 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 15/20 | 0.53 |
| ▸ | MPEG1 | Q2M385 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163654 | 0.84 | HKDC1 (0.69) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL3413590 | 0.84 | HKDC1 (1.00) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL197917 | 0.84 | HKDC1 (0.56) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL10787959 | 0.79 | HKDC1 (0.50) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL9654553 | 0.78 | HKDC1 (0.67) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL31189916 | 0.78 | HKDC1 (0.50) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL15212939 | 0.78 | ALOX5 (0.50) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL9578693 | 0.77 | ALOX5 (0.67) | HKDC1CDC25ACDC25BIDO1ALOX5 | |
| SCHEMBL9578682 | 0.77 | ALOX5 (0.77) | HKDC1ALOX5MPEG1 | |
| SCHEMBL14507728 | 0.76 | HKDC1 (0.47) | HKDC1CDC25ACDC25BIDO1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-3708673-B1 | METHOD AND DEVICE FOR ELECTRONICALLY CONTROLLING THE PH OF A SOLUTION | BOSCH GMBH ROBERT (DE) | 2025-03-26 | — | — | EP | disclosed |
| EP-3320410-B1 | ELECTRONIC CONTROL OF THE PH OF A SOLUTION CLOSE TO AN ELECTRODE SURFACES | BOSCH GMBH ROBERT (DE) | 2024-09-25 | — | — | EP | disclosed |
| US-11561198-B2 | Electronic control of the pH of a solution close to an electrode surface | ROBERT BOSCH GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BERG, KARA ANN | 2022-06-30 | — | — | US | disclosed |
| US-10942146-B2 | Electrochemically active agents for pH modulation in biological buffers | ROBERT BOSCH GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| EP-3320332-B1 | METHODS FOR GENERATING PH/IONIC CONCENTRATION GRADIENT NEAR ELECTRODE SURFACES FOR BUBBLE DETECTION USING ELECTRODES | BOSCH GMBH ROBERT (DE) | 2021-03-03 | — | — | EP | disclosed |
| EP-3708673-A1 | METHOD AND DEVICE FOR ELECTRONICALLY CONTROLLING THE PH OF A SOLUTION | Robert Bosch GmbH (DE) | 2020-09-16 | — | — | EP | disclosed |
| CN-109843896-A | Hydroxycinnamic acid derivatives, methods and uses thereof | 波尔图大学 | 2019-06-04 | — | — | CN | disclosed |
| EP-0141996-B1 | TRIPHENDIOXAZINE REACTIVE DYES | BAYER AG (DE) | 1987-11-25 | — | — | EP | disclosed |
| EP-0229339-A2 | Water soluble triphene dioxazine compounds, their starting compounds containing sulphonyl groups, process for their preparation and use of the triphene dioxazines as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-22 | — | — | EP | disclosed |
| EP-0144580-B1 | TRIPHENDIOXAZINE DYES | BAYER AG (DE) | 1987-07-08 | — | — | EP | disclosed |
| EP-0222098-A2 | Water soluble triphenodioxazine compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-05-20 | — | — | EP | disclosed |
| US-4629788-A | COLORFASTNESS; BLUE COLOR; NATURAL AND SYNTHETIC FIBER | BAYER AKTIENGESELLSCHAFT (DE) | 1986-12-16 | — | — | US | disclosed |
| US-4621138-A | Triphendioxazine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| US-4591643-A | Triphendioxazine reactive dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-27 | — | — | US | disclosed |
| EP-0158882-A2 | Triphenedioxazine dyes | BAYER AG (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0144580-A2 | Triphendioxazine dyes | BAYER AG (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0141996-A2 | Triphendioxazine reactive dyes | BAYER AG (DE) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10942146-B2 | Electrochemically active agents for pH modulation in biological buffers | CA2, PDE7A, CA1 | HKDC1 1453/4885CDC25A 515/4885CDC25B 573/4885 |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | HKDC1 3148/4885CDC25A 1435/4885CDC25B 1225/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | HKDC1 1983/4885CDC25A 2375/4885CDC25B 1829/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | HKDC1 3148/4885CDC25A 1435/4885CDC25B 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.